BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21079194)

  • 1. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?
    Cozzolino M; Mazzaferro S; Brandenburg V
    Nephrol Dial Transplant; 2011 Feb; 26(2):402-7. PubMed ID: 21079194
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
    Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
    Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phosphate binders : What are the recent evidences ?].
    Bouajila IA; Martin PY; De Seigneux S
    Rev Med Suisse; 2017 Feb; 13(551):468-472. PubMed ID: 28714648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Should we consider the cost-effectiveness analysis to apply the recommendations for phosphate-binders administration?].
    Martín de Francisco AL
    Nefrologia; 2008; 28(2):129-34. PubMed ID: 18454700
    [No Abstract]   [Full Text] [Related]  

  • 7. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).
    Biggar P; Ketteler M
    Expert Opin Pharmacother; 2010 Nov; 11(16):2739-50. PubMed ID: 20977406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Iron-based Phosphate Binders for ESRD Patients].
    Cozzolino M; Mangano M; Magagnoli L; Di Lullo L; Galassi A; Brancaccio D; Bellasi A
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F
    G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.
    West SL; Swan VJ; Jamal SA
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S41-7. PubMed ID: 20089502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate management in chronic kidney disease.
    Bhan I
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of hyperphosphatemia ; phosphate-binder].
    Yokoyama K
    Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Education for dialysis patients lowers long-term phosphate levels and maintains health-related quality of life.
    Gardulf A; Pålsson M; Nicolay U;
    Clin Nephrol; 2011 Apr; 75(4):319-27. PubMed ID: 21426886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
    Galassi A; Cupisti A; Santoro A; Cozzolino M
    J Nephrol; 2015 Aug; 28(4):415-29. PubMed ID: 25245472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for hyperphosphatemia in feline CKD: what's out there?
    Kidder AC; Chew D
    J Feline Med Surg; 2009 Nov; 11(11):913-24. PubMed ID: 19857854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.